| [1] |
Siegel RL, Miller KD, Jemal A, et al. Cancer statistics, 2018[J]. CA Cancer J Clin，2018，68(1)：7-30.
|
| [2] |
Lim B, Woodward WA, Wang X, et al. Inflammatory breast cancer biology: the tumour microenvironment is key[J]. Nat Rev Cancer，2018，18(8)：485-499.
|
| [3] |
Saberi-Karimian M, Katsiki N, Caraglia M，et al. Vascular endothelial growth factor: An important molecular target of curcumin[J]. Crit Rev Food Sci Nutr, 2019，59(2)：299-312.
|
| [4] |
Fouad TM, Barrera AMG, Reuben JM, et al. Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system[J]. Lancet Oncol，2017，18(4)：e228-e232.
|
| [5] |
Masuda H, Brewer TM, Liu DD, et al. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes [J]. Ann Oncol, 2014，25(2)：384-391.
|
| [6] |
Kupstas AR, Hoskin TL, Day CN, et al. Biological subtype, treatment response and outcomes in inflammatory breast cancer using data from the National Cancer Database[J]. Br J Surg，2020, 107(8)：1033-1041.
|
| [7] |
Costa R, Santa-Maria CA, Rossi G, et al. Developmental therapeutics for inflammatory breast cancer: Biology and translational directions[J]. Oncotarget，2017，8(7)：12 417-12 432.
|
| [8] |
Schlichting JA, Soliman AS, Schairer C, et al. Inflammatory and non-inflammatory breast cancer survival by socioeconomic position in the Surveillance, Epidemiology, and End Results database, 1990-2008[J]. Breast Cancer Res Treat，2012，134(3)：1257-1268.
|
| [9] |
Das A, Mahapatra S, Bandyopadhyay D, et al. Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: A network meta-analysis[J]. Crit Rev Oncol Hematol，2021，157：103 186.
|
| [10] |
Bose D, Banerjee S, Singh RK, et al. Vascular endothelial growth factor encoded by Parapoxviruses can regulate metabolism and survival of triple negative breast cancer cells[J]. Cell Death Dis，2020, 11(11)：996.
|
| [11] |
Aalders KC, Tryfonidis K, Senkus E, et al. Anti-angiogenic treatment in breast cancer: facts, successes, failures and future perspectives[J]. Cancer Treat Rev, 2017，53：98-110.
|
| [12] |
Deryugina EI, Quigley JP. Tumor angiogenesis: MMP-mediated induction of intravasation and metastasis sustaining neo-vasculature[J]. Matrix Biol，2015，44-46：94-112.
|
| [13] |
Koutras A, Kotoula V, Fountzilas G, et al. Prognostic and predictive role of vascular endothelial growth factor polymorphisms in breast cancer[J]. Pharmacogenomics，2015，16(1)：79-94.
|
| [14] |
Apte RS, Chen DS, Ferrara N. VEGF insignaling and disease: beyond discovery and development[J]. Cell, 2019，176(6)：1248-1264.
|
| [15] |
Coelho AL, Gomes MP, Catarino RJ, et al. Angiogenesis in NSCLC: is vessel co-option the trunk that sustains the branches? [J]．Oncotarget，2017，8(24)：39 795-39 804.
|
| [16] |
Mohamed TK, Batran RZ, Elseginy SA, et al. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis[J]. Bioorg Chem，2019，85：253-273.
|
| [17] |
Madu CO, Wang S, Madu CO, et al. Angiogenesis inbreast cancer progression, diagnosis, and treatment[J]. J Cancer, 2020，11(15)：4474-4494.
|
| [18] |
Linderholm BK, Lindh B, Beckman L，et al. Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers[J]. Clin Breast Cancer, 2003, 4(5)：340-347.
|
| [19] |
Adams J, Carder PJ, Downey S, et al. Vascular endothelial growth factor in breast cancer. Comparison of plasma, serum, and tissue VEGF and micro vessel density and effects of tamoxifen[J]. Cancer Res，2000，60(11)：2898-2905.
|
| [20] |
Foekens JA, Peters HA, Grebenchtchikov N, et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer[J]. Cancer Res, 2001，61：5407-5414.
|
| [21] |
Van der Auwera I, Van Laere SJ, Van den Eynden GG, et al. Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification[J]. Clin Cancer Res, 2004，10(23)：7965-7971.
|
| [22] |
Arias-Pulido H, Chaher N, Gong Y, et al. Tumor stromal vascular endothelial growth factor A is predictive of poor outcome in inflammatory breast cancer[J]. BMC Cancer，2012，12：298.
|
| [23] |
Folkman J. Tumor angiogenesis: therapeutic implications [J]. N Engl J Med，1971，285：1182-1186.
|
| [24] |
Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities[J]. Cell Mol Life Sci，2020，77(9)：1745-1770.
|
| [25] |
Garcia J, Hurwitz HI, Sandler AB，et al. Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook[J]. Cancer Treat Rev, 2020，86：102 017.
|
| [26] |
Hey SP, Gyawali B, D’Andrea E，et al. A systematic review and meta-analysis of bevacizumab in first-line metastatic breast cancer：lessons for research and regulatory enterprises[J]. J Natl Cancer Inst, 2020，112(4)：335-342.
|
| [27] |
Li Q, Wang Y, Jia W, et al. Low-dose anti-angiogenic therapy sensitizes breast cancer to PD-1 blockade[J]. Clin Cancer Res，2020，26(7)：1712-1724.
|
| [28] |
Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer[J]. N Engl J Med，2007，357(26)：2666-2676.
|
| [29] |
Robert NJ, Diéras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase Ⅲ trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer[J]. J Clin Oncol, 2011，29(10)：1252-1260.
|
| [30] |
Brufsky AM, Hurvitz S, Perez E, et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase Ⅲ trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer[J]. J Clin Oncol，2011，29(32)：4286-4293.
|
| [31] |
Miles D, Cameron D, Bondarenko I, et al. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase Ⅲ trial with prospective biomarker evaluation[J]. Eur J Cancer，2017，70：146-155.
|
| [32] |
Dickler MN, Barry WT, Cirrincione CT, et al. Phase Ⅲ trial evaluating letrozole as first-line endocrine therapy with or without bevacizumab for the treatment of postmenopausal women with hormone receptor-positive advanced-stage breast cancer: CALGB 40503 (Alliance)[J]. J Clin Oncol，2016，34(22)：2602-2609.
|
| [33] |
Gligorov J, Doval D, Bines J, et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomized, open-label, phase 3 trial[J]. Lancet Oncol，2014，15(12)：1351-1360.
|
| [34] |
Spalding BJ. Thumbs up for avastin[J]. Nat Biotechnol，2008，26(4)：365.
|
| [35] |
Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer[J]. J Clin Oncol，2006，24(5)：769-777.
|
| [36] |
Bertucci F, Fekih M, Autret A, et al. Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study[J]. Lancet Oncol，2016，17：600-611.
|
| [37] |
Pierga JY, Petit T, Delozier T, et al. Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study[J]. Lancet Oncol，2012，13：375-384.
|
| [38] |
Pierga JY, Petit T, Levy C, et al. Pathological response and circulating tumor cell count identifies treated HER2t inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data[J]. Clin Cancer Res，2015，21(6)：1298-1304.
|
| [39] |
Nahleh ZA, Barlow WE, Hayes DF, et al. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer[J]. Breast Cancer Res Treat，2016，158：485-495.
|
| [40] |
Palazzo A, Dellapasqua S, Munzone E, et al. Phase Ⅱ trial of bevacizumab plus weekly paclitaxel, carboplatin, and metronomic cyclophosphamide with or without trastuzumab and endocrine therapy as preoperative treatment of inflammatory breast cancer[J]. Clin Breast Cancer，2018，18(4)：328-335.
|
| [41] |
Lenzer J. FDA committee votes to withdraw bevacizumab for breast cancer[J]. BMJ, 2011, 343：d4244.
|
| [42] |
Tabouret E, Bertucci F, Pierga JY, et al. MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study[J]. Oncotarget，2016，7(14)：18 531-18 540.
|
| [43] |
Pierga JY, Bidard FC, Autret A, et al. Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase Ⅱ trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab[J]. Ann Oncol，2017，28：103-109.
|
| [44] |
Overmoyer B, Fu P, Hoppel C, et al. Inflammatorybreast cancer as a model disease to study tumor angiogenesis: Results of a phase IB trial of combination SU5416 and doxorubicin[J]. Clin Cancer Res，2007，13(19)：5862-5868.
|
| [45] |
Cristofanilli M, Johnston SR, Manikhas A，et al. A randomized phase Ⅱ study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer[J]. Breast Cancer Res Treat，2013，137(2)：471-482.
|